|
|
Genomic Health (GHDX)This is an EDITABLE stock research wiki. You can contribute by clicking on the EDIT PAGE link above or on the page icons that appear when you roll over one of the category subtitles below. From 1Table of contents
Company Information:Company Address: 301 Penobscot Drive Redwood City, CA 94063
Company’s Web Address: http://www.genomichealth.com/
Industry Sector:
Fiscal Year: Dividend:
Note: this section is not editable.
Please click here to report any inaccuracies.
Company Overview:Note: this section is not editable.
Genomic Health Inc. is an oncology-based biotech company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The company's first product, Oncotype DX, is used for early stage breast cancer patients to predict the likelihood of cancer recurrence, the likelihood of patient survival within 10 years of diagnosis and the likelihood of chemotherapy benefit. All tumor samples are sent to the company's laboratory in Redwood City, California for analysis. Upon generation and delivery of a Recurrence Score report to the physician, the company generally bills third-party payers for Oncotype DX. The list price of the test is $3,650. The company is also developing a genetic test to determine the correlation between gene expression and colon cancer recurrence in patients. On October 4, 2005, the company completed an initial public offering of 5 million shares of its common stock at $12.00 per share. Net proceeds from the offering after deducting underwriting discounts, commissions and expenses were $53.5 million. On the closing of the company's initial public offering, all of the convertible preferred stock outstanding automatically converted into 16.2 million shares of common stock and a dividend of 0.65 million common share was distributed to stockholders. An additional $5.0 million was raised on October 4, 2005, through the private sale of 0.42 million shares of common stock to Incyte Corporation, a related party. Again in May 2007, the company issued 3.45 million shares of its common stock, including the fully exercised over-allotment option, at $15.50 per share. The net proceeds from this offering are approximately $49.7 million. Genomic Health was founded in 2000 and is headquartered in Redwood City, California.
Valuation:Enter Valuation Analysis and Valuation Ratios Here
Projected Financials:Income Statement: (Paste Here) Balance Sheet: (Paste Here) Cash Flow Statement: (Paste Here) Financial Ratios: (Paste Here) Other: (Paste Here) News:
Tags:
none
The opinions and views expressed in this document do not necessarily reflect the views or opinions of InvestingMinds. InvestingMinds did not prepare and does not endorse such content. Please note that it is intended for general circulation only and the recommendations contained herein do not take into account the specific investment objectives, financial situation or particular needs of any particular person. This document is for information purposes only and it should not be regarded as an offer to sell or as a solicitation of an offer to buy securities or other instruments. No part of this document may be reproduced in any manner without the written permission of InvestingMinds.
|
||||||||||||||||||||||||||||||
|
|